Pramlintide (CAT#: TP-007CL)

Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.


  • Datasheet
  • MSDS
  • COA

Specifications

  • Classify
  • Protein therapeutics replacing a protein that is deficient or abnormal: Endocrine disorders (hormone deficiencies)
  • Therapeutic
  • Pramlintide acetate
  • Trade Name
  • Symlin
  • Function
  • Mechanism unknown; recombinant synthetic peptide analogue of human amylin (a naturally occurring neuroendocrine hormone regulating post-prandial glucose control)
  • Examples of clinical use
  • Diabetes mellitus, in combination with insulin

References

  • Synonyms
  • Not Available

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TP-007CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare